Join to View Full Profile
1836 South AveLa Crosse, WI 54601
Phone+1 608-782-7300
Fax+1 608-775-6334
Dr. Rosenstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lori Rosenstein is a hematologist in La Crosse, WI and is affiliated with Gundersen Lutheran Medical Center. She received her medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 15 years. She is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2005 - 2009- University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2002 - 2005
University of Wisconsin School of Medicine & Public HealthClass of 2002
Certifications & Licensure
IA State Medical License 2002 - 2026
MN State Medical License 2022 - 2026
WI State Medical License 2014 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- The Art of Oncology Education and Knowledge Sharing-It is All About the "How".Guilherme Sacchi de Camargo Correia, Lori J Rosenstein, Rohit Gosain, Rami Manochakian
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2025-06-01 - Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, Grzegorz S Nowakowski, Christopher Fletcher
Blood Cancer Journal. 2025-05-12 - 33 citationsStandard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.Usha Perepu, Isaac Matthew Chambers, Abdul Wahab, Patrick Ten Eyck, Chaorong Wu
Journal of Thrombosis and Haemostasis. 2021-07-18
Press Mentions
Match Day Numbers Show “Promising” Change in Radiation OncologyMarch 24th, 2025
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
